Our vision is clear – to eliminate patient harm associated with infiltrations.
We are engineers and doctors. Inventors and technologists. Nurses and researchers. Teachers and scientists.
We are all united by a common mission: to provide affordable and innovative technology to improve the safety of patients by reducing the risks associated with IV infiltrations. It is our guiding purpose and the reason we love the work we do.
Message from our President & CEO, Gary Warren
Over the past few years, our company has grown from really a small group of people doing nothing but research and development – essentially an incubator startup type of company – to a company with over 30 people including marketing, sales, manufacturing and clinical teams.
After we received our first FDA clearance, we had to “grow up” and we put in place all the manufacturing and associated systems to be compliant with the laws associated with building medical devices. You can’t do that in a garage. We could have contracted much of the manufacturing out but that didn’t align with our goal of building a real company and solving a real problem.
We have assembled an incredible group of people here at ivWatch and we are always looking to add to this talented group. It is very rewarding to see everyone and everything click to help shipments go out the door. I do get asked all the time what our “exit strategy” is and I can tell you everyone here feels it is the same: Solve this problem. I want to type in “IV Infiltration” into a search engine in 10 years and the horrible images are gone.
Employee Spotlight: Leah Moore, Director Marketing
I joined ivWatch in 2015, shortly after the company received FDA Clearance for the Model 400. The most exciting thing about my role is the ability to help build and establish the company brand and increase awareness for ivWatch and our products.
Because we are constantly developing new tools and material, I have the chance to work with all the teams within the organization to help keep the messaging and look consistent for our brand. The entire team is dedicated to our vision of eliminating harm associated with IV infiltrations, so we want to make sure we effectively communicate that passion and commitment to our customers.
OUR LEADERSHIP TEAM
Gary Warren serves as President & CEO of ivWatch and oversees all aspects of operations and strategic direction for the company. Gary brings more than 30 years of experience with high-technology companies with a proven track record of creating successful organizations in rapidly emerging markets. Over his career Gary has had executive experience in developing and managing high-growth technology and venture-backed private companies with a focus on product management and delivery in small start-up companies, large public companies, and government programs.
Prior to ivWatch, Gary held the role of President & CEO of AppForge a leading enterprise mobile software provider that was privately held and venture capital-backed. Following AppForge, Gary was the managing partner and founder of IPX Partners, Inc. a business development consulting firm. Earlier in his career, Gary held the role of Senior Vice President at Symantec Corporation where he was responsible for numerous programs, including product development, research/advanced concepts, business development, including mergers and acquisitions, strategic investments and partnerships. Gary began his career as a Research Scientist in computational fluid dynamics at NASA Langley Research Center and moved to a Program Manager for the high-performance computing and communications group.
Susan Brown is responsible for the clinical research and training programs for ivWatch. Prior to her position at ivWatch, Susan spent 15 years at Children’s Hospital of the King’s Daughter’s (CHKD) specializing in pediatric intensive care and ended her tenure in the position of Director of Patient Care Services. During her time at CHKD, her responsibilities included managing operational and clinical care departments, including departments responsible for patient flow, vascular access, resource pool, and neonatal/pediatric critical care transport.
Jason Naramore is the Chief Technology Officer and oversees the ivWatch Core Science team that is responsible for the design, research and technology for the company product lines. Jason joined ivWatch in 2012.
Jason is listed as co-inventor on 20 published U.S. utility applications, 4 published PCT (international) applications and 10 national/regional stage applications. Jason began his career at CW Optics performing early prototyping and advancing the technology that is part of the current ivWatch product. Following his time at CW Optics, Jason gained medical device research, development and manufacturing experience at Canon Virginia, Inc.
Scott Hensley leads the sales function for ivWatch. Prior to his role at ivWatch, Scott held progressively more senior sales roles during his 13 years at Masimo Corporation where he facilitated sales revenue growth year over year. During his tenure, Scott achieved strong sales growth by leading his teams in identifying and implementing sales strategies to convert and standardize hospitals and hospital systems with key products such as patient monitoring equipment, software parameter upgrades, and disposable products.
Mike Gahan oversees all of our operations for ivWatch. Mike joined ivWatch in 2016 with over 25 years of experience in managing the operations of large and small scientific and medical companies. Prior to joining ivWatch, Mike was Vice President of Operations at Transnetyx, Inc, a molecular diagnostics company where he led day to day operations including management of medical lab technicians and medical technologies, engineering and inventory management.
Mike spent 17 years at Ciba Specialty Chemicals where he held various roles including development engineer, automation engineer, production engineer, programs manager, project leader and operations manager.
John Gahan is responsible for development and maintenance of the ivWatch manufacturing processes. John joined ivWatch in 2016 from Luxottica Optical Manufacturing where he held progressively senior roles in engineering and facility leadership, ending his tenure at Luxottica as Engineering Director.
Previous roles within his 30 years of experience include positions at Baxter Medical and Becton Dickenson where he led automation efforts in manufacturing an assembly process in clean-room environments, and the redesign of manufacturing lines.
Leah Moore leads the development and execution of strategic marketing, branding and public relations for ivWatch. Prior to ivWatch, she served as Marketing Director for AppForge where she helped position the company as a leading enterprise mobile software provider. Previous to AppForge, Leah held various marketing roles within Symantec Corporation, including managing the global marketing strategy for the Enterprise Norton Anti-Virus product. She has proven experience building new companies and product lines with comprehensive global go to market plans for new technology products, partners programs, and services.
Chuck Egress is the Director of Product Delivery for ivWatch where he oversees the development, road map, supplier partnerships and go-to-market activities for the ivWatch product line. He joined ivWatch in 2015 with over 27 years of experience working with advanced technology companies and products at start-ups as well as large organizations.
Prior to joining ivWatch, Chuck a spent 12 years at Symantec Corporation, followed by 7 years at McAfee/Intel Corporation where he had a proven track record of bringing new technologies to market and driving growth from zero to multi-million dollar businesses in dynamic, global markets. These various roles provided extensive experience in developing new business, owning P&L for product lines, managing engineering, product management and guiding channel and distribution activities. Prior to his years in at Symantec and Intel, Chuck helped to grow two successful software companies, including URLabs, which sold to Symantec in 1999.
Holly Novak is responsible for ensuring compliance to all applicable standards and leads the ivWatch Quality Management System (QMS). Prior to joining ivWatch, Holly has spent the past 15 years in various roles within R&D, Production and Quality Assurance for products that required both USDA and FDA clearance.
In her most recent positions, Holly implemented and maintained an ISO compliant Quality Management System for a medical device company, and more recently for a global supplier of raw materials that served the pharmaceutical, device, government agencies and university markets. She also played an instrumental role in attaining CE marking for the entire product line for Maine Standards Company, a market leader for linearity and calibration verification products.
Scott Anchell is responsible for designing, drafting and prosecuting the ivWatch patent portfolio. Scott joined ivWatch in 2011 with more than 28 years of experience procuring patents in the United States and elsewhere in the world, including the extensive ivWatch patent portfolio of 80 utility patent application filings at the USPTO, 8 PCT (international) patent application filings and 15 patent applications filed in the patent offices of Australia, Canada, Europe, Israel, and Japan.
Prior to ivWatch, Scott was employed as a patent agent at several Tier 1 patent law firms, including Drinker Biddle & Reath, Morgan Lewis & Bockius, and served as a Senior Patent Agent at the law firm Perkins Coie.